Core Viewpoint - Spectral AI has announced a significant repricing of its publicly-traded common share purchase warrants, reducing the exercise price from $11.50 to $2.75 per share, which is expected to enhance liquidity and attract more investors [1][2]. Group 1: Warrant Repricing - The repricing of the warrants applies uniformly to all outstanding warrants and was executed in accordance with the Company's discretion as permitted under the Warrant Agreement [2]. - The Company will provide at least twenty days prior written notice to the registered holders of the warrants regarding the reduction [2]. Group 2: Financial Implications - If all warrants are exercised for cash, Spectral AI may receive up to approximately $23 million in net proceeds [3]. Group 3: Company Overview - Spectral AI is a Dallas-based predictive AI company focused on medical diagnostics, particularly in wound care, aiming to improve treatment decisions for conditions such as burns and diabetic foot ulcers [4]. - The Company utilizes its DeepView® System, which provides clinicians with an objective assessment of a wound's healing potential, thereby enhancing patient outcomes and reducing healthcare costs [4].
Spectral AI Announces Repricing of its Public Warrants